Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.